ORGO CEO updates Form 4 equity award details

Organogenesis Holdings Inc. President and CEO Gary S. Gillheeney reported updated equity compensation activity.

Rhea-AI Filing Summary

Organogenesis Holdings Inc. President and CEO Gary S. Gillheeney reported updated equity compensation activity. On February 18, 2026, he acquired 188,856 shares of Class A common stock as a grant or award at $0.00 per share, and disposed of 91,311 shares at $3.84 per share to cover tax obligations. The amendment corrects the numbers previously reported for the performance share vesting and related tax-withholding, with no other changes to the original Form 4.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Gillheeney Gary S.

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	188,856	$0.00	$0.00
Exercise Price or Tax Liability	Class A Common Stock	91,311	$3.84	$351K

Holdings After Transaction: Class A Common Stock — 4,232,087 shares (Direct)

Footnotes (1)

1. F1. This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ORGO CEO Gary S. Gillheeney report on this amended Form 4?

Gary S. Gillheeney reported two updated transactions. He received a grant of 188,856 shares of Class A common stock at $0.00 per share and disposed of 91,311 shares at $3.84 per share to satisfy tax obligations tied to a performance share award.

Why was the Organogenesis (ORGO) Form 4 amended for Gary S. Gillheeney?

The Form 4 was amended to correct share counts previously reported. It adjusts the number of shares acquired upon vesting and settlement of a performance share award and the number of shares withheld to cover tax obligations; no other aspects of the original filing were changed.

How many ORGO shares did Gary S. Gillheeney acquire in the amended Form 4?

He acquired 188,856 shares of Organogenesis Class A common stock. The transaction is classified as a grant, award, or other acquisition with a reported price of $0.00 per share, linked to vesting and settlement of a performance share award described in the amendment note.

How many ORGO shares were disposed of for taxes in Gary S. Gillheeney’s amended Form 4?

He disposed of 91,311 shares of Class A common stock. This disposition was coded as F, meaning shares were withheld or delivered at $3.84 per share to pay the exercise price or satisfy tax liabilities connected with the performance share award vesting.

What do the transaction codes A and F mean in Gary S. Gillheeney’s ORGO Form 4/A?

Code A indicates a grant, award, or other acquisition of 188,856 shares. Code F reflects a tax-withholding disposition of 91,311 shares, where shares are used to cover the exercise price or tax liabilities associated with equity compensation.

Did the amended ORGO Form 4 change anything besides the share numbers for Gary S. Gillheeney?

According to the disclosure, the amendment only corrects the number of shares acquired and withheld. It explicitly states that no other changes were made to the original Form 4 filing beyond these numerical corrections for the performance share award and related tax-withholding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 04:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gillheeney Gary S.

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/18/2026		A		188,856(1)	A	$0	4,323,398	D
Class A Common Stock	02/18/2026		F		91,311(1)	D	$3.84	4,232,087	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.

	/s/ William R. Kolb, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.